Accelerating Therapeutic DiscoveryTM

News From The Alpha-1 Project

10
The Alpha-1 Project, the venture philanthropy arm of the Alpha-1 Foundation, today announced it will fund a two-year postdoctoral fellowship position at the National Institutes of Health’s (NIH) National Center for Advancing Translational Sciences (N...

[Read More...]

13
CORAL GABLES, FL (January 13, 2014) – The Alpha-1 Project, a venture philanthropy company created to speed development of new therapies and potential cures for lung and liver diseases caused by Alpha-1 Antitrypsin Deficiency, announced a partne...

[Read More...]

10
MIAMI, FL and WORCESTER, MA (Jan. 8, 2014) – The Alpha-1 Project (TAP) today announced a commission to the University of Massachusetts Medical School (UMMS) to develop a PiZ antibody. The antibody will be used to track the presence of mutant al...

[Read More...]

01
SAN DIEGO, August XX, 2013—Carolus Therapeutics, Inc. and The Alpha-1 Project, Inc. (TAP), a wholly-owned subsidiary of the Alpha-1 Foundation, today announced that they are collaborating  to characterize human biological samples for the p...

[Read More...]

20

MIAMI, FL and BOSTON, MA, April 19, 2013 – The Alpha-1 Project (TAP) today announced a $150,000 commission to Darrell Kotton, MD, to expand development of induced pluripotent stem cell (iPSC) lines created from tissue donated by patients with Alpha-1 Antitrypsin Deficiency (Alpha-1). Kotton is Professor of Medicine and Co-director of both The Alpha-1 Center and the Center for Regenerative Medicine at Boston University School of Medicine and Boston Medical Center.

“We are happy to announce The Alpha-1 Project’s investment in providing tools for researchers and industry,” said Jean-Marc Quach, Executive Director of TAP. “This commission signals our intent to direct research and resources aimed at speeding the development of new therapies for Alpha-1. I must emphasize that additional funds will need to be raised from the community if Dr. Kotton is to meet the goal of completing 20 stem cell lines over the next three years.”

Kotton plans to make the Alpha-1 iPSC lines available to all researchers interested in studying stem cell technology and possible therapies for Alpha-1.

[Read More...]

Page 3 of 4First   Previous   1  2  [3]  4  Next   Last